TABLE 2.
Type of DILI and mechanism of damage of different approved drugs used for therapy of COVID‐19, adapted from Liver Tox
| Drugs | Type of DILI | Mechanism of liver injury |
|---|---|---|
| Chloroquine | Hepatocellular | Hypersensitivity, idiosyncratic |
| Azithromycin |
Cholestatic hepatitis (more frequent) Hepatocellular |
Hypersensitivity, idiosyncratic |
| Acetaminophen | Hepatocellular | Dose‐dependent |
| Lopinavir/ritonavir | Hepatocellular, cholestatic or mixed | Due to liver metabolism by the cytochrome P450 system (CYP3A4), which may result in the production of a toxic intermediate |
| Tocilizumab | Hepatocellular, predominantly cholestatic | Linked to effects on the immune system or on the IL‐6 pathway, which is important in liver regeneration |
| Remdesivir | Hepatocellular | Idiosyncratic |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.